NDA 216962 · Abbvie
Vyalev
Foscarbidopa, Foslevodopa · Subcutaneous
OrphanLast checked: Nov 19, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Oct 16, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
3 Phase 3, 0 recruiting
FAERS reports
8,815
7,502 serious, 1,446 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 19, 2026.
VYALEV is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). VYALEV is a combination of foscarbidopa (an aromatic amino acid decarboxylation inhibitor) and foslevodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. ( 1 )
Mechanism: VYALEV is a prodrug combination of foscarbidopa (carbidopa-4´-monophosphate) and foslevodopa (levodopa-4´-monophosphate). Foscarbidopa and foslevodopa are converted in vivo to carbidopa and levodopa. Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 16, 2024 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination OrphanLetterLabelReview
1 products under this application
- VYALEV · FOSCARBIDOPA 120MG/10ML; FOSLEVODOPA 2400MG/10ML (12MG/ML · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Foscarbidopa" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03781167 · 244 participants · Start Apr 29, 2019 · Primary completion Aug 17, 2022
Drug: ABBV-951 · For: Parkinson's Disease (PD)
Sites: Birmingham, Alabama; Sun City, Arizona; Fountain Valley, California · 65 sites in all
- Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's DiseasePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04379050 · 130 participants · Start Jun 8, 2020 · Primary completion Apr 17, 2026
Drug: ABBV-951 · For: Parkinson's Disease (PD)
Sites: Birmingham, Alabama; Sun City, Arizona; Aurora, Colorado · 51 sites in all
- Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's DiseasePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04750226 · 118 participants · Start Feb 18, 2021 · Primary completion Apr 27, 2026
Drug: ABBV-951 · For: Parkinson's Disease (PD)
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 52 sites in all
AbbVieAbbVie (ABBV)
NCT05094050 · 16 participants · Start Jan 18, 2022 · Primary completion Mar 17, 2023
Drug: ABBV-951 · For: Parkinson's Disease
Sites: Aurora, Colorado; Washington D.C., District of Columbia; Chicago, Illinois · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- on and off phenomenon1,211
- fall1,137
- hallucination892
- death758
- dyskinesia731
- tremor513
- device issue488
- general physical health deterioration465
- mobility decreased461
- infusion site erythema430
- malaise412
- asthenia397
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 380 |
| 2025 | 4,254 |
| 2026 | 4,179 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ, Aldred J, Budur K, et al. · Lancet Neurol 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease.
Aldred J, Bouchard M, Martínez-Castrillo JC, et al. · Mov Disord Clin Pract 2026 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.
Chaudhuri KR, Facheris MF, Bergmans B, et al. · Mov Disord Clin Pract 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
Rosebraugh M, Stodtmann S, Liu W, et al. · Parkinsonism Relat Disord 2022 · Clinical Trial, Phase I, Randomized Controlled Trial
- Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.
Savaryn JP, Smith RL, Rosebraugh M, et al. · Pharmacol Res Perspect 2024 · Randomized Controlled Trial
- Patients' experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson's disease.
Soileau M, Kumar R, Parab A, et al. · J Neurol 2025 · Clinical Trial, Phase III
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.